| 0.6912 0.047 (7.26%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94  |
1-year : | 1.08 |
| Resists | First : | 0.81 |
Second : | 0.92 |
| Pivot price | 0.72 |
|||
| Supports | First : | 0.63 | Second : | 0.52 |
| MAs | MA(5) : | 0.67 |
MA(20) : | 0.74 |
| MA(100) : | 1.06 |
MA(250) : | 1.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 9.4 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 3.05 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MIST ] has closed above bottom band by 32.0%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.7 |
| Low: | 0.63 - 0.64 | 0.64 - 0.64 |
| Close: | 0.68 - 0.69 | 0.69 - 0.7 |
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Fri, 23 Oct 2026
Milestone Pharmaceuticals Stock Price Forecast. Should You Buy MIST? - StockInvest.us
Fri, 23 Oct 2026
Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations - Yahoo Finance
Tue, 18 Aug 2026
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Wed, 12 Aug 2026
Milestone Pharmaceuticals shares tumble after Q2 earnings miss - Yahoo Finance
Tue, 11 Aug 2026
What To Expect From Milestone Pharmaceuticals Inc (MIST) Q2 2026 Earnings - Yahoo Finance
Tue, 09 Jun 2026
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -42 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.245e+008 (%) |
| Held by Institutions | 1.0647e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.3e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.69 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 584.9 % |
| Return on Equity (ttm) | -42.8 % |
| Qtrly Rev. Growth | 522.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -466.21 |
| EBITDA (p.s.) | 1.80612e+006 |
| Qtrly Earnings Growth | -7.821e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.02 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 1.901e+007 |
| Forward Dividend | 1.736e+007 |
| Dividend Yield | 2750290000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|